STAT5B

Across TCGA pan-cancer cohorts, STAT5B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STAT5B data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STAT5B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STAT5B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where STAT5B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.928	0.105	.006	35	view →
LUAD	OS	Tertile	III,IV	0.188	0.840	.008	23	view →
PDAC	OS	Quartile	III,IV	0.798	0.153	.013	6	view →
GBM	OS	Quartile	All	0.627	0.399	.004	5	view →
HNSC	DFS	Tertile	II,III,IV	0.932	1.000	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STAT5B–CCRCC (DFS)

Open the CCRCC breakdown →